NCT00181688: Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer |
|
|
| Completed | 2 | 35 | US | Iressa (ZD1839), Arimidex (Anastrozole) | Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital | Ovarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma | 03/06 | 03/06 | | |
NCT00049556: Gefitinib in Treating Patients With Cervical Cancer |
|
|
| Completed | 2 | | US | gefitinib, immunohistochemistry staining method, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy, sentinel lymph node biopsy | National Cancer Institute (NCI) | Cervical Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | | 08/06 | | |
NCT00189358: A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy |
|
|
| Completed | 2 | | Europe | ZD1839, tamoxifen | AGO Study Group | Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer | | | | |
